ストックスクリーナーアプリを入手
3.58
3.50%
-0.13
アフターアワーズ：
3.57
-0.01
-0.28%
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 12-Month LowTime to Sell? - MarketBeat
Recursion reports grant of inducement awards as permitted by the Nasdaq Listing Rules - marketscreener.com
Recursion Pharmaceuticals stock hits 52-week low at $3.53 - Investing.com
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - marketscreener.com
TechBio firm Recursion grants 820K stock units to 17 new hires - Stock Titan
Baillie Gifford's Strategic Adjustment in Recursion Pharmaceuticals Inc - GuruFocus
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Trade Below Fair Value Estimate - Yahoo Finance
This $4 Stock Could Be Your Ticket to Millionaire Status - The Globe and Mail
Recursion Pharmaceuticals stock hits 52-week low at $3.78 By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares - MarketBeat
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k By Investing.com - Investing.com Nigeria
Borgeson Blake sells Recursion Pharmaceuticals (RXRX) shares for $924k - Investing.com
Recursion Pharmaceuticals Stock Jumps on Promising TUPELO Trial Results - StocksToTrade
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $8.66 Million Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Biotech Stocks To Add to Your WatchlistFebruary 5th - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 52-Week LowWhat's Next? - MarketBeat
Boardroom Moves Shake Recursion Pharma Stock - timothysykes.com
Recursion Pharmaceuticals stock hits 52-week low at $3.78 - Investing.com
Recursion Pharmaceuticals (RXRX) Stock Analysis: Biotech Innovator with 67% Potential Upside - DirectorsTalk Interviews
OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha
Here’s what JP Morgan thinks about Recursion Pharmaceuticals (RXRX) - MSN
Is Recursion Pharmaceuticals Inc. (RXRX) the best overlooked penny stock to invest in? - MSN
Short Squeeze: Is Recursion Pharmaceuticals Inc forming a bullish divergenceJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Setups: Is Recursion Pharmaceuticals Inc forming a bullish divergence2025 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - Yahoo Finance
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift - Newswire Canada
Forget 2025: These 2 Growth Stocks Could Soar in 2026 - AOL.com
Recursion Pharmaceuticals Faces Challenges and Opportunities - Intellectia AI
Can This Beaten-Down AI Stock Bounce Back in 2026? - The Globe and Mail
Can This Beaten-Down AI Stock Bounce Back in 2026? - The Motley Fool
Risk Analysis: Will Canadian Solar Inc benefit from green energy policiesPortfolio Value Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Exploring a 52.51% Potential Upside in Biotech - DirectorsTalk Interviews
Aug Final Week: Will Recursion Pharmaceuticals Inc benefit from green energy policies2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Will Nvidia-Backed BioHive-2 and Big Pharma Alliances Redefine Recursion Pharmaceuticals' (RXRX) Narrative - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Valuation Check After Analyst Optimism Insider Buying And Nvidia AI Partnership - simplywall.st
Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? - Finviz
Is Recursion (RXRX) Turning Nvidia-Backed AI Hype Into a Durable Drug Discovery Advantage? - Sahm
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Recursion Pharma director Gibson sells $178,800 in stock By Investing.com - Investing.com Canada
Recursion Pharma director Gibson sells $178,800 in stock - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 10.8%Here's Why - MarketBeat
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
Recursion Shines at J.P. Morgan Healthcare Conference - StocksToTrade
Recursion Pharmaceuticals Boosts Visibility With J.P. Morgan Conference - timothysykes.com
How Do Investors Really Feel About Recursion Pharmaceuticals Inc? - Benzinga
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):